Low plasma adiponectin concentration is an indicator of the metabolic syndrome

Merja Santaniemi, Y Antero Kesäniemi and Olavi Ukkola
Department of Internal Medicine and Biocenter Oulu, University of Oulu, PO Box 5000, 90014 Oulu, Finland
(Correspondence should be addressed to M Santaniemi; Email: merja.santaniemi@oulu.fi)

Abstract

Objective: Adiponectin is an adipocytokine known to be decreased in obesity. It functions in glucose and fatty acid metabolism and also has an anti-inflammatory role in microvasculature. We wanted to investigate the role of adiponectin as a biomarker of metabolic syndrome (MS) and see how the plasma adiponectin levels relate to new criteria of MS proposed by the International Diabetes Federation.

Methods: Plasma adiponectin concentrations were measured from total of 1041 Finnish subjects with an ELISA – a novel method planned in our laboratory.

Results: In both the sexes, the plasma adiponectin levels were lower in subjects with MS when compared with subjects with no diagnosis of MS (\( P < 0.001 \)). Plasma adiponectin levels did not differ between subjects with National Cholesterol Education Program (ATPIII) and International Diabetes Federation-defined MS. Lower adiponectin levels were associated with different components of the MS and there was a trend towards decreasing adiponectin levels with an increasing number of components of MS in both the sexes. Subjects in the lowest adiponectin quartile had a significantly higher probability of having MS (\( P < 0.001 \)), 4.4-fold in males and 7.5-fold in females, when compared with the corresponding individuals in the highest quartile. The probability increased in every lowering quartile of adiponectin level and was independent of body mass index.

Conclusion: We conclude that adiponectin levels correlate with most of the components of the MS and the metabolic cluster per se.

European Journal of Endocrinology 155 745–750

Introduction

Obesity, in particular visceral adiposity, is known to be associated with insulin resistance and a heterogeneous disorder, metabolic syndrome (MS). The MS is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity (1). These disorders have cardiovascular consequences and thus obesity can be seen as a major public health issue. The adipokine hypothesis is one of the physiological mechanisms used to explain how excess body fat leads to numerous health consequences. Adiponectin is an adipokine secreted specifically from the adipose tissue. The inverse relationship between body fat and serum adiponectin levels has been demonstrated, and weight reduction can increase adiponectin levels (2, 3). Adiponectin modulates glucose metabolism by having insulin-sensitising effects (4–6). Adiponectin also decreases circulating free fatty acid concentrations and muscle triglyceride content by stimulating fatty acid oxidation in muscle via AMP-activated protein kinase (AMPK) (6, 7). Thus, adiponectin is a hormone that links adipose tissue and whole-body glucose metabolism. Low adiponectin levels have been associated with type 2 diabetes and insulin resistance (8, 9). Adiponectin has been found to have vasoprotective and anti-inflammatory effects and therefore could be viewed as a potential link between MS and its cardiovascular consequences. In the present study, we wanted to investigate the relationship between plasma adiponectin levels and the different components of MS in a large, population-based sample of middle-aged subjects. A special interest was to explore how adiponectin levels relate to the new worldwide definitions of MS proposed by the International Diabetes Federation (IDF).

Subjects and methods

Subjects

The subjects are participants of Oulu Project Elucidating the Risk of Atherosclerosis study, which is a population-based epidemiological study addressing the risk factors and disease end points of atherosclerotic cardiovascular diseases. The study group consisted of 1045 subjects randomly selected from Finnish national population register. The participating study subjects visited the
research laboratory of the Department of Internal Medicine of the University of Oulu. At this visit, a standardised health questionnaire covering the past medical history, present and former medication use, physical activity, smoking habits, alcohol consumption and family history was administered by two specially trained study nurses. The details of the study have been previously described (10). The study design is cross-sectional. The main characteristics of study group are shown in Table 1. Plasma adiponectin level was measured from a total of 1041 subjects.

### Clinical measurements

Laboratory analyses were obtained after an overnight fast and plasma was separated by centrifugation and stored at $-20^\circ\text{C}$. The fasting glucose, insulin, lipoprotein fractions, total cholesterol and triglycerides were measured as previously described (14). C-reactive protein was determined by the quick-index ($1/(\log(\text{fasting insulin}) + \log(\text{fasting glucose}))$) (11). $\gamma$-Glutamyl transpeptidase (GGT) activity was measured using the method according to the European Committee for Clinical Laboratory Standards.

Plasma adiponectin concentrations were measured with an ELISA devised in our laboratory. Monoclonal anti-human adiponectin antibody (R&D-systems, Cat. MAB10651) was used as a capture antibody and biotinylated monoclonal anti-human adiponectin antibody (R&D-systems, Cat. BAM1065) was used as a detection antibody. Both antibodies were used in a sandwich ELISA kit (Diagnostics Systems Laboratories). Insulin sensitivity was determined by the method according to the European Committee for Clinical Laboratory Standards. The fasting glucose, insulin, lipoprotein fractions, total cholesterol and triglycerides were measured as previously described (14). C-reactive protein was determined by the quick-index ($1/(\log(\text{fasting insulin}) + \log(\text{fasting glucose}))$) (11). $\gamma$-Glutamyl transpeptidase (GGT) activity was measured using the method according to the European Committee for Clinical Laboratory Standards.

### Statistical methods

Statistical analysis was performed by SPSS version 11.5. The linear regression coefficient between the observed adiponectin concentration and the control sample was statistically significant ($R^2 = 4.2\%$, $P < 0.0005$) permitting the correction of adiponectin measurements for the inter-assay variation using the linear regression analysis. Thus, the adiponectin levels were corrected according to the formula $X_a = X - ac(c-C)$; where $X_a$ is the individual's adjusted adiponectin concentration; $X$ is the individual's observed adiponectin concentration; $ac$ is the regression coefficient of the observed adiponectin concentration with the concentration of the control sample; $c$ is the mean value of all the control samples. The inter-assay variation was 15.9% before and 6.5% after correction.

![Image](https://via-free-access.bioscientifica.com/)

**Table 1** The main characteristics of the study group as means (s.d.) or frequencies (percentages).

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>516</td>
<td>516</td>
</tr>
<tr>
<td>Age (years)</td>
<td>50.69 (5.99)</td>
<td>51.79 (5.95)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.97 (4.22)</td>
<td>27.47 (5.05)</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>152.06 (21.36)</td>
<td>144.84 (22.06)</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>92.57 (11.98)</td>
<td>85.56 (12.00)</td>
</tr>
<tr>
<td>Total serum cholesterol (mmol/l)</td>
<td>5.77 (1.05)</td>
<td>5.62 (1.06)</td>
</tr>
<tr>
<td>LDL (mmol/l)</td>
<td>3.66 (0.94)</td>
<td>3.40 (0.93)</td>
</tr>
<tr>
<td>HDL (mmol/l)</td>
<td>1.20 (0.30)</td>
<td>1.49 (0.38)</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.78 (1.08)</td>
<td>1.40 (0.94)</td>
</tr>
<tr>
<td>Blood glucose (mmol/l)</td>
<td>4.87 (1.57)</td>
<td>4.64 (1.38)</td>
</tr>
<tr>
<td>Plasma adiponectin (µg/ml)</td>
<td>13.70 (5.60)</td>
<td>17.51 (6.34)</td>
</tr>
<tr>
<td>Type 2 diabetics n</td>
<td>52 (10%)</td>
<td>41 (7.8%)</td>
</tr>
</tbody>
</table>

BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein.
divided into quartiles by keeping mean, +1 S.D. and −1 S.D. as limits. Logistic regression analysis was used to define the odds for MS in adiponectin quartiles using adiponectin quartiles alone as well as using the body mass index (BMI) and age as covariates. A P value of <0.05 was considered statistically significant.

Results

Correlations of adiponectin levels with various parameters of metabolic syndrome

The mean plasma adiponectin level in the study population was 15.6 mg/l (S.D. 6.28). The mean level in women was 17.51 mg/l (S.D. 3.4) and 13.70 mg/l (S.D. 5.60) in men, with the difference between the sexes being statistically significant (P=0.009). The presence of medication for type 2 diabetes may influence the relationship between plasma adiponectin and fasting glucose or quick-index. Therefore, the correlations were calculated after excluding those patients receiving medication. A total of 18 men (3.4%) and 12 women (2.5%) were excluded. In males, adiponectin levels were negatively and statistically significantly correlated with BMI (R² = −0.187, P<0.001), waist-to-hip-ratio (R² = −0.180, P<0.001), fasting insulin (R² = −0.193, P<0.001) and glucose (R² = −0.089, P=0.046), triglycerides (R² = −0.226, P<0.001) and C-reactive protein (CRP) (R² = −0.087, P=0.049). In females, adiponectin levels were negatively and statistically significantly correlated with BMI (R² = −0.240, P=0.03), waist-to-hip-ratio (R² = −0.295, P<0.001), fasting insulin (R² = −0.301, P<0.001) and glucose (R² = −0.187, P<0.001), triglycerides (R² = −0.213, P<0.001) and CRP (R² = −0.207, P<0.001). Adiponectin levels correlated positively and statistically significantly with HDL-cholesterol (R² = −0.254, P<0.001 in males and R² = −0.295, P<0.001 in females) and quick-index (R² = −0.192, P<0.001 in males and R² = −0.297, P<0.001 in females). We also found adiponectin to be correlated negatively with liver enzymes ALAT (R² = −0.163, P<0.001 in males and R² = −0.21, P<0.001 in females) and GGT (R² = −0.091, P=0.038 in males and R² = −0.181, P<0.001 in females).

Adiponectin and IDF-defined components of MS

There were a total of 388 subjects (37.6% of all) with MS defined by IDF in the study population and 308 subjects (29.8%) with MS defined by NCEP (ATPIII). A total of 223 (43% of men) men and 165 (32% of women) women had MS defined by IDF criteria, whereas 32.1% of men and 26.9% of women had MS defined by NCEP (ATPIII). In both the sexes and with both criteria of MS, the plasma adiponectin levels were lower in the subjects with MS compared with those without the syndrome (P<0.001). Plasma adiponectin levels did not differ between the groups with differentially diagnosed MS. Males having MS defined by IDF criteria had the plasma adiponectin of 12.3 mg/l and those having MS defined by NCEP (ATPIII) 12.1 mg/l. In females, the corresponding values were 14.8 and 14.5 mg/l respectively.

Adiponectin levels were compared with the different components of the MS defined by IDF. Tables 2 and 3 reveal the mean adiponectin concentrations in relation to the clinical features of the MS. We observed that lower adiponectin levels were associated with most features.

The study subjects were grouped on the basis of how many components of MS based on the IDF definition could be diagnosed. To evaluate the association between the multiplicity of components of MS and the hypoadiponectemia, adiponectin levels were compared between groups (Fig. 1). Adiponectin levels decreased in conjunction with the increase in the number of metabolic abnormalities in both sexes.

Using binary logistic regression, we calculated the odds ratio (OR) of the MS as predicted by adiponectin quartiles. Both males and females were divided into four groups based on their plasma adiponectin levels. The ORs were first defined in unadjusted model using only adiponectin quartiles as covariates. The probability of MS was defined as changes in the odds of the event (Exp(B)) compared with fourth quartile, which had the lowest probability to have MS (Fig. 2). In both the sexes, the odds of having MS was increased in every lower quartile of adiponectin level and thus the probability of having MS was highest in the first adiponectin quartile. Binary logistic model was further adjusted by age, smoking years, grams of alcohol consumption per day, blood pressure medication and lipid medication. In males, the probability to have MS in the third quartile after adjustments was 1.6 (95% CI: 0.8–2.9, P=0.153), in the second quartile it was 1.9 (95% CI: 1.0–3.3, P=0.040) and in the first quartile it was 3.1 (95% CI: 1.5–6.3, P=0.002) when compared with those not having the component of MS in males.

Table 2 Adiponectin levels as means (s.d.) in subjects positive to individual component of metabolic syndrome (MS) according to International Diabetes Federation (IDF) criteria and in subjects not having the component of MS in males.

<table>
<thead>
<tr>
<th>Plasma adiponectin (mg/l)</th>
<th>Males</th>
<th>No IDF-criteria fulfilled</th>
<th>IDF criteria fulfilled</th>
<th>Student’s t-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic syndrome</td>
<td>n=293; 14.47</td>
<td>n=233; 12.28</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Waist</td>
<td>n=201; 15.01</td>
<td>n=315; 12.86</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>n=311; 14.5</td>
<td>n=205; 12.5</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>HDL</td>
<td>n=364; 14.46</td>
<td>n=152; 11.86</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>n=45; 16.09</td>
<td>n=471; 13.46</td>
<td>P=0.003</td>
<td></td>
</tr>
<tr>
<td>Plasma glucose</td>
<td>n=387; 13.74</td>
<td>n=129; 13.56</td>
<td>P&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

*Mann–Whitney U-test. HDL, high density lipoprotein.

www.eje-online.org
the fourth quartile. In females, the probability of having MS in the third quartile after adjustments was 1.5 (95% CI: 0.7–3.3, $P = 0.305$), in the second quartile it was 4.2 (95% CI: 2.0–8.8, $P < 0.001$) and in the first quartile it was 9.4 (95% CI: 4.1–21.4, $P < 0.001$) when compared with the fourth quartile.

**Discussion**

Hypoadiponectinemia has already been associated with the risk of the MS in several populations (14–19). Therefore, measurement of adiponectin levels has been considered as being a useful biomarker or even a target for the management of the MS. However, in most reports, the number of subjects has been rather small, and to our knowledge, there are no studies on the plasma adiponectin levels in relation to MS defined on the basis of the new criteria of IDF. In the present study, we analysed a large population of middle-aged Finnish men and women to find out how plasma adiponectin levels are associated with MS defined on the basis of the new criteria. The study allowed us to consider sex-specific differences in adiponectin levels and their interaction with MS. As expected, the adiponectin levels were higher in women than in men (20). In both the sexes, we found that adiponectin was correlated negatively with measures of body fat, fasting plasma glucose and triglycerides and hs-CRP. A positive correlation was found between adiponectin and quick-index, fasting plasma insulin and HDL-cholesterol. These correlations reflect the role of adiponectin in the modulation of insulin sensitivity and cholesterol metabolism. In agreement with the postulated role of adiponectin in modulating liver function (21, 22), we also found the correlations of adiponectin and liver enzymes. In our study, a significant difference was noted in adiponectin levels in both the sexes between subjects with MS and those without MS. Despite the differences in definitions of MS, both NCEP- and IDF-defined subjects had low plasma adiponectin levels and both criteria seem to work similarly in the sense of finding subjects with low adiponectin levels. In the new criteria of MS proposed by the IDF, central obesity is a prerequisite risk factor. The involvement of adiponectin in the waist criteria is not surprising since adiponectin

**Table 3** Adiponectin levels as means (s.d.) in female subjects positive to individual component of MS according to International Diabetes Federation criteria, and in those not having the component of MS.

<table>
<thead>
<tr>
<th>Component of MS</th>
<th>No IDF-criteria fulfilled</th>
<th>IDF criteria fulfilled</th>
<th>Student's $t$-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic syndrome</td>
<td>$n = 315; 18.81 (6.3)$</td>
<td>$n = 165; 14.74 (5.6)$</td>
<td>$P &lt; 0.001$</td>
</tr>
<tr>
<td>Waist</td>
<td>$n = 233; 18.94 (6.4)$</td>
<td>$n = 282; 16.27 (6.0)$</td>
<td>$P &lt; 0.001$</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>$n = 398; 18.32 (6.4)$</td>
<td>$n = 118; 14.77 (5.33)$</td>
<td>$P &lt; 0.001$</td>
</tr>
<tr>
<td>HDL</td>
<td>$n = 352; 18.60 (5.4)$</td>
<td>$n = 164; 15.17 (5.13)$</td>
<td>$P &lt; 0.001$</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>$n = 96; 18.25 (6.2)$</td>
<td>$n = 420; 17.22 (6.4)$</td>
<td>$P = 0.203$</td>
</tr>
<tr>
<td>Plasma glucose</td>
<td>$n = 420; 18.18 (6.3)$</td>
<td>$n = 96; 14.57 (5.8)$</td>
<td>$P &lt; 0.001^a$</td>
</tr>
</tbody>
</table>

$^a$Mann–Whitney $U$-test.

**Figure 1** Adiponectin levels according to positive features of MS in females and males. The boxes represent means and the bars represent s.d. The number of subjects is presented in parentheses.
concentrations are primarily determined by the degree of the visceral fat. In addition, adiponectin seems to have an important role, independent of BMI, on the HDL and the triglyceride levels. According to recent reports (23, 24), adiponectin may contribute to the regulation of hepatic lipase activity and represent the link between the insulin-resistant conditions and high plasma triglycerides and low HDL-cholesterol. In support of the latter hypothesis, adiponectin levels were significantly lower, in our study, in those patients with low HDL-cholesterol or high triglyceride levels. Considering the IDF criteria of blood pressure, lower adiponectin levels were seen in both sexes in the group of higher blood pressure, but the difference was statistically significant only in males. Adiponectin levels were lower in female subjects with positive criteria of blood glucose component of MS compared with those not having this component. Our results suggest that in females, low adiponectin levels were even more related to the probability of having MS compared with the role in males (Fig. 2). Interestingly, it has been found that females have higher proportions of high molecular weight and hexameric forms of adiponectin and lower proportions of trimers, and that the higher molecular form adiponectin serves as a precursor pool for activation by metabolic stimuli, such as an increased insulin level (20). Therefore, adiponectin could partly explain the better insulin sensitivity of females and could also be one reason why lower adiponectin levels have more deleterious effects in women. Our study is cross-sectional, which does not allow us to infer causality from our results. For example, we cannot

![Figure 2](https://example.com/figure2.png)

Figure 2 The odds ratio (OR) of the MS as predicted by adiponectin quartiles in (a) males and (b) females in an unadjusted model. The normal distribution of plasma adiponectin levels is shown and the division into quartiles is presented. The probability to have MS is presented as odds ratios (95% confidence interval) compared with the fourth quartile. At the top of quartile boxes are the numbers of subjects in each quartile and the percentiles of subjects having MS.
conclude whether the decreased adiponectin levels are a cause or a consequence of the metabolic state of high glycaemia, dyslipidaemia or inflammation. The major finding of our study was that in both the sexes, those subjects in the lowest adiponectin quartile exhibited a significantly higher probability of having MS when compared with those in the highest quartile. The probability was found to increase in every lowering quartile of the adiponectin level and was independent of BMI. In conclusion, we suggest that adiponectin is a marker of the MS and a marker of the multiplicity of components of MS according to the new criteria of the IDF.

Acknowledgements

This study was supported by the Medical Council of the Academy of Finland and the Finnish Foundation for Cardiovascular Research. We acknowledge the excellent technical assistance of Ms Helena Kalliokoski, Ms Saija Kortetjärvi, Ms Sirpa Rannikko and Ms Liisa Mannermaa.

References


